Morvarid Golrokh Mofrad1, Behrang Kazeminezhad2, Ebrahim Faghihloo3. 1. Human Viral Vaccine Department, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran. 2. Department of Pathology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Departments of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract
INTRODUCTION: Breast cancer (BC) is the most common malignancy affecting females worldwide. Various risk factors play a role in the developing of BC. Infectious agents like viruses have been proposed for this cancer and Epstein-Barr virus (EBV) is a widely researched candidate virus. This study detects the presence of EBV-DNA in breast cancer patients. METHODS: The study was conducted on 59 formalin-fixed paraffin-embedded (FFPE) tissue blocks samples of women with breast carcinoma and 11 non-neoplastic breast controls. The DNA was extracted for all the samples. Then detection of EBNA1 EBV was done by polymerase chain reaction (PCR). RESULTS: EBV was detected in 6.7% (4/59) of patients while all breast control samples were negative. All patients with positive EBV-DNA were high tumor grades (II, and III). Also, they had a low level of educations. CONCLUSIONS: According to our findings, it can be suggested that EBV may have a potential role in breast cancer development. However, this study provides substantial but not conclusive evidence for the involvement of viruses in BC disease development. Therefore, future investigations are needed to elucidate the exact role of EBV in breast cancer.<br />.
INTRODUCTION:Breast cancer (BC) is the most common malignancy affecting females worldwide. Various risk factors play a role in the developing of BC. Infectious agents like viruses have been proposed for this cancer and Epstein-Barr virus (EBV) is a widely researched candidate virus. This study detects the presence of EBV-DNA in breast cancerpatients. METHODS: The study was conducted on 59 formalin-fixed paraffin-embedded (FFPE) tissue blocks samples of women with breast carcinoma and 11 non-neoplastic breast controls. The DNA was extracted for all the samples. Then detection of EBNA1EBV was done by polymerase chain reaction (PCR). RESULTS:EBV was detected in 6.7% (4/59) of patients while all breast control samples were negative. All patients with positive EBV-DNA were high tumor grades (II, and III). Also, they had a low level of educations. CONCLUSIONS: According to our findings, it can be suggested that EBV may have a potential role in breast cancer development. However, this study provides substantial but not conclusive evidence for the involvement of viruses in BC disease development. Therefore, future investigations are needed to elucidate the exact role of EBV in breast cancer.<br />.
Entities:
Keywords:
Epstein - Barr virus; PCR; breast cancer
Breast Cancer (BC) is one of the most prevalent cancers among females and also it’s the
primary cause of high morbidity and mortality due to malignancies in the world. There is an
enormous difference in breast cancer survival rates worldwide, with an evaluated 5-year
survival of 80% in developed countries to below 40% for developing countries (DCs) (Coleman
et al., 2008).In the US, this rate is about 90%. However the incidence of breast cancer is
lower in DCs, but the ratio of the mortality is higher(Parkin et al., 2005; Allemani et al.,
2015). Roughly 60% of deaths due to breast cancer occur in DCs, whereas in developed
countries, more than 200 cases per 100,000 women are diagnosed per year (van Netten et al.,
1987; Tsutsui et al., 2002; Talvensaari-Mattila et al., 2003; Torre et al., 2015).
Unfortunately, breast cancer is diagnosed in the late stages in DCs because in these
countries early detection, diagnosis, and treatment cannot be adequately promoted (Anderson
et al., 2006). Breast cancer can be metastatic cancer and can frequently move to other
organs such as the bone, liver, lungs, and brain, which mostly responsible for its incurable
potential. Early diagnosis can lead to a worthy prognosis and a high survival rate (DeSantis
et al., 2016).BC is a multifactorial disease and various risk factors for this disease have been
identified, like age, geographical variation, age at menarche and menopause, age at first
pregnancy, family history, previous benign breast disease, radiation, lifestyle (includes :
Diet, Weight, Alcohol intake, Smoking) and oral contraceptive (Kamińska, Ciszewski et al.,
2015). Some viruses such as humancancer such as human papillomaviruses and Epstein-Barr
virus have been implicated in the pathogenesis of breast cancer (Akhter et al., 2014).Epstein - Barr virus (EBV) is one of the most common human viruses and infects about 95% of
the world’s population (Khan and Hashim, 2014). It’s a ubiquitous gamma herpesvirus causes
infectious mononucleosis and also it is related with the development of different
Malignancies like Burkitt’s lymphoma, Hodgkin’s disease, B-cell lymphoma in
immunocompromised individuals, nasopharyngeal carcinoma (NPC) and T-cell lymphoma, gastric
carcinoma, and thymus and lung malignancies (Niedobitek, 2000; Takeuchi et al., 2004; Khan
and Hashim, 2014; Oh and Weiderpass 2014; Gru et al., 2015).EBV can entry to epithelial cells with the help of ligands that exists on the surface of
B-cells, called CD21 or CR2 or EBVR (Borza and Hutt-Fletcher, 2002). EBV infection is mostly
latent in target cells. EBV latency is characterized by a limited expression of viral
proteins (latency III): i.e., six nuclear proteins EBNA-1, EBNA-2, EBNA-3A-C, EBNA-LP, and
three latent membrane proteins (LMP-1, LMP-2A, and LMP-2B) (Kang and Kieff, 2015).Different laboratories have reported the detection of EBV in a subset of breast tumors
(Labrecque et al., 1995; Luqmani and Shousha, 1995; Bonnet et al., 1999). Although, negative
results have also been reported (Dadmanesh et al., 2001; Deshpande et al., 2002; El-Naby et
al., 2017). EBV infection inclines breast epithelial cells to malignant transformation
through activation of HER2/HER3 signaling cascades. HER2 and HER3 are two of the cellular
oncogenes known to be involved in humanbreast cancer development (Hu et al., 2016).A large number of epidemiological studies have shown the association between EBV infection
and breast carcinoma like a meta-analysis study of Huo Q et al. So the result was
remarkable, they found 29.32% of the patients with BC were infected with the Epstein-Barr
virus. And the prevalence of EBV was highest in Asia (35.25%) and lowest in the USA (18.27%)
(Huo et al., 2012).Therefore in this article, we study the prevalence of EBV infection in female breast cancerpatients from Modarres Hospital in Iran.
Materials and Methods
Tumor specimensThis study includes 59 tumorFormalin-Fixed Paraffin-embedded (FFPE) samples selected from
the clinical archives of Modarres Hospital, Tehran, Iran. Specimens collected from women
diagnosed with BC from 2008 to 2019. Also, we collected 11 non-tumoral specimens. For
further studies, we transferred specimens to the school of medicine at Shahid Beheshti
University.DNA ExtractionFor standard polymerase chain reaction (PCR), genomic DNA (gDNA) was extracted from
formalin-fixed paraffin-embedded (FFPE) breast tissues using chemical agents such as xylene.
At first FFPE tissues were cut about 10 μm thick using microtome and for removing paraffin
from tissue section, we added 1 ml xylene and they mixed on the rotator. Then centrifuged
for 5 min and remove the supernatant. Afterward, we repeated these steps one more time.
Next, we added 1 ml of 96% ethanol. For drying the ethanol; we put each microtube in heating
block 50ºC until ethanol was completely evaporated. Next, we used the digestion buffer and
proteinase K solution in each tube. Then we incubated them one overnight.The next day we put microtubes in 95ºC heater. Then we added phenol and centrifuged them
for 5 min and have added the phenol-chloroform solution to each microtube. In the next step,
we added only chloroform. In the end, we added ethanol and put them into the incubator for
one overnight.On the third day of extraction, we centrifuged samples for 30 min at maximum speed at 4ºC.
Then we discarded SN and left the ethanol to dry in 37ºC heater. At the last step, we added
distilled water to them, and then the gDNA extracts were quantified with a Nano Drop
spectrophotometer.PCRThe quality control of the extracted DNA was done by using polymerase chain reaction (PCR)
for Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the specific primers listed in
Table2.
Table 2
List of Primers Used for the Amplification of GAPDH and EBV Gene Sequences
Gene to beamplified
Primer code
Sequence (5’-3’)
GAPDH (200 bp)
GAPDH-F
ATGTTCGTCATGGGTGTGAA
GAPDH-R
GGTGCTAAGCAGTTGGTGGT
EBV- EBNA (280 bp)
EBNA-F
TGAATACCACCAAGAAGGTG
EBNA-R
AGTTCCTTCGTCGGTAGTC
Thirty cycles of GAPDH amplification were performed in a DNA thermal cycler (Bio
Intellectica) with the following conditions: denaturing at 95°C for 30 s, hybridization at
55°C for 30 s, and elongation at 72°C for 30s, followed by a final elongation at 72°C for 10
min.And PCR for EBV was carried out in a total volume of 25 μl using Taq DNA polymerase
(Takapouzist, Iran) with the following conditions: 95°C for 5 min; followed by 35 cycles of
95°C, 30 s; 60°C, 30 s; 72°C, 30s; and a final extension at 72 °C for 10 min. Ten
microliters of each PCR product was analyzed by electrophoresis in agarose gel. The PCR
product size is 250 bp. Reactions containing approximately 25 μl without any DNA were run as
negative controls and DNA from B95-8 cell lines as a positive control.
Results
A total of 70 FFPE samples were included in this study. 59 patients were classified as
cases (malignant breast disease), and the remaining 11 as controls. All of the breast cancer
samples gave the expected band after amplification with the GAPDH. Then PCR for EBNA-1 was
done. Of the 59 cases, 4 were positive for the presence of EBV (6.7%), and No positivity was
noted in the control samples.The details for the clinical and pathological findings for FFPE breast cancer samples
include age group, grading of breast cancer, type of BC, and level of education are
collected in Table 1.
Table 1
Clinical and Pathological Features of Paraffin-Embedded Samples of Breast Cancer
(BC).
Clinical and pathological characteristics of
BC patients
Number of patients; N (%)
Age
Young (<30)
4 (6.7)
Adult (30-50)
19 (32.2)
Old (>50)
36 (61.01)
Grade
I (low grade)
4 (6.7)
II/ III (high grade)
55 (93.2)
Type of BC
Invasive lobular
3 (5.08)
Invasive ductal
56 (94.9)
Education degree
High level
14 (23.7)
Low level
34 (57.6)
No degree
11 (18.6)
The median age of the patients was about 50 years (range, 29 to 81 years). Our study
included cases of female breast cancer only. Histologically, tumors type were lobular (about
5 %) and ductal carcinoma (about 95 %). All positive samples for EBV were ductal type.We had 4 patients (6.7%) with a low-grade malignancy (tumor grade I), and all remaining had
high tumor grades (II, and III) (93.3%). And all positive cases had high grades (II, and
III). 57.6% of patients had low educational degrees and even 18.6 % had no degrees and
others (23.7%) had high degrees.Agarose Gel Electrophoresis of PCR Amplification for the EBNA Gene in BCPatients. Lane
1 shows amplification of 250 bp EBNA gene fragment of EBV from BCpatient's sample. Lane
NC (negative control), includes distilled water. Lane PC (positive control), includes
the B95-8 cell line. Lane L represents a 100bp ladderClinical and Pathological Features of Paraffin-Embedded Samples of Breast Cancer
(BC).List of Primers Used for the Amplification of GAPDH and EBV Gene Sequences
Discussion
Breast cancer is a multifactorial disease; the role of the infectious agent in this disease
is remarkable. The high incidence of breast cancer around the world has got the scientist’s
attention to the viral etiology of BC. Though many studies have been done, no etiologic
factors for humanbreast cancer have been known. Recent researches have shown the
association of breast cancer and viral infections, such as Epstein–Barr virus (EBV), Human
papillomavirus (HPV) and mouse mammary tumor virus (MMTV) (Naushad et al., 2017). The first
study of the detection of EBV in breast carcinoma has been described in 1995 by Labrecque LG
and his colleagues. They reported 19 positive samples (21%) from 91 cases of breast
carcinoma and blood samples by using PCR (Labrecque et al., 1995).In this study, we considered EBV in BC cases. In the current study, we identified 4
EBV-positive breast tumor cells using PCR for EBNA-1. Our findings are consistent with the
results published by others such as the study of Reza MA et al. which was done in the
southeast of Iran (Kerman). They revealed the role of EBV in breast carcinoma in 2015. They
demonstrated it by using real-time PCR and Immunohistochemistry (IHC) techniques. The
presence of EBV was 8/100 (8%), and they stated p53 was suppressed in EBV positive samples
(Reza et al., 2015).Also, Naushad et al in 2017 could detect EBV in Pakistani breast cancerpatients with a
prevalence of 24% by using PCR (Naushad et al., 2017). Sharifpour et al., (2019) have
observed 27.02% EBV DNA type 1 in the FFPE tissue of Iranian patients with ductal breast
carcinoma in 2019 and the detection of EBV DNA was done by nested PCR.Ballard in (2015) has shown an EBV presence (39.4%) in ductal and lobular tumor types by
EBNA1 staining.Mario et al., (2010) studied the characterization of EBV Latency Pattern in ArgentineBreast Carcinoma. They used IHC with monoclonal antibodies and in situ hybridization to find
out EBV genomic DNA and EBNA1 expression in 31% (22/71) of patients while all breast control
samples were negative for both viral DNA and EBNA1 protein. And LMP2A was detected in 73% of
EBNA1 positive cases (Lorenzetti et al., 2010).A tissue microarray study was performed in 2015 by Aboulkassim et al., (2015) they could
report 51.58% presence of EBV in 108 breast cancer tissues collected from Syrian women.Findings of H Arbach et al showed that EBV genomes can be detected by Q-PCR in about half
of tumor specimens, usually in low copy numbers. On the other hand, they also found that the
viral load is highly variable from tumor to the tumor (Arbach et al., 2006).Although negative results have also been reported as the study of Glaser et al, which
reported negative results in 107 cases using EBER1 transcripts by in situ hybridization,
This study included specimens from 21 hospitals in 7 counties from the San Francisco Bay
Area of northern California, and it embraced age, sex, and ethnic groups associated with
variation in breast cancer incidence in the United States (Glaser et al., 1998).Similarly, Gaffey et al., (1993) found no evidence of EBV in 16 medullary carcinomas or 18
infiltrating breast carcinomas using PCR.Also in another study, Lespagnard et al., (1995), couldn’t find EBV in 10 medullary
carcinomas by using PCR EBER in situ hybridization, and IHC for LMP1.Besides in Iran, Dowran et al., (2019) studied on 300 breast biopsy tissues and PCR assay
was performed, but they didn’t report any genomic DNA fragment of EBV.There is controversy regarding the role of EBV in the pathogenesis of BC. The controversy
is influenced by two reasons: technical limitations and duration of fixation. This study
demonstrated the presence of EBV genome malignant tumor tissues in women with breast lesions
by using PCR assay; more studies need to be analyzed in order to establish the exact role of
this virus in the pathogenesis of breast cancer, and utilizing more techniques like
Immunohistochemistry or real-time PCR in addition of PCR (Arbach et al., 2006; Joshi et al.,
2009; Lorenzetti et al., 2010).Furthermore, Greer et al., (1991) reported that detection of EBV by PCR in formalin
preserved specimens are affected greatly by the duration of fixation. Likewise in our study,
we found all DNA positive samples from new specimens collected during 2 years (2018 to
2019). And we couldn’t find any positivity from old specimens (2008 to 2018).About the grade of malignancy, we had 4 patients with a low-grade malignancy (tumor grade
I), and all remaining had high tumor grades (II, and III). And all positive specimens for
the EBV had a high-grade tumor. One of them was grade II and three of them were grade III.
So we can conclude from our results and other articles, there is an association between the
presence of EBV and the grade of tumors (Bonnet et al., 1999; Ribeiro-Silva et al., 2004;
Preciado et al., 2005).Income and education have a strong association with the incidence of breast cancer (Devesa
and Diamond, 1980), for example, Liu et al., (2017) performed a multi-center 10-year
epidemiological study which determined the impact of the education level of Chinese female
breast cancer (4,211 cases). For patients within the lower educational group, the tumor
grade was higher and the rates of investigations were lower, as were the rates of
radiotherapy, chemotherapy, and endocrine therapy. Similarly, in our study, most of the
patients had a low level of education. So there is a very urgent need for regular learning
courses for the practice of breast cancer screening especially for that person with less
educational level.In conclusion, according to our findings and review of other studies, it can be determined
that EBV may have an etiologic role in breast cancer. In our study, all positive samples
were in a high grade of the tumor. So we can conclude, there is a relationship between the
presence of EBV and the grade of the tumor. Higher grades show more possibility of the
presence of EBV. Another factor was the level of education, which has an important role in
the check-up and follows up during the disease. Also, all of the positive cases were women
with a low level of education.Thus our results with 6.7% EBV-DNA positivity supports the possibility of an etiologic role
of EBV in the induction and development of BC, and other factors such as age, level of
education, the grade of tumor and new techniques should be considered. So more studies using
more specific and sensitive techniques are needed.
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young Journal: Lancet Oncol Date: 2008-07-17 Impact factor: 41.316
Authors: A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu Journal: Curr Hematol Malig Rep Date: 2015-12 Impact factor: 3.952